EP0551400A1 - Method for treating inflammation using anti-idiotypic antibodies - Google Patents
Method for treating inflammation using anti-idiotypic antibodiesInfo
- Publication number
- EP0551400A1 EP0551400A1 EP91918758A EP91918758A EP0551400A1 EP 0551400 A1 EP0551400 A1 EP 0551400A1 EP 91918758 A EP91918758 A EP 91918758A EP 91918758 A EP91918758 A EP 91918758A EP 0551400 A1 EP0551400 A1 EP 0551400A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- icam
- antibody
- ab2β
- binding
- recited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 title claims description 12
- 230000004054 inflammatory process Effects 0.000 title claims description 12
- 230000027455 binding Effects 0.000 claims abstract description 39
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 38
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 38
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 8
- 230000001419 dependent effect Effects 0.000 claims abstract description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 17
- 230000003302 anti-idiotype Effects 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 5
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims 1
- 230000003053 immunization Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000002776 aggregation Effects 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102100025390 Integrin beta-2 Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a method for inhibiting ICAM-]-dependent inflammatory responses utilizing anti-ICAM-1 anti-idiotype antibodies or fragments thereof.
- this invention relates to a method for treating ICAM-1-dependent inflammation in a patient by immunizing the patient with a sufficient amount of an anti-ICAM-1 anti-idotype antibody to induce an immune response against ICAM-1-bearing cells.
- Cellular adhesion is a process through which leukocytes attach to cellular substrates, such as endothelial cells, in order to migrate from circulation to sites of ongoing in lammation, and properly defend the host against foreign invaders such as bacteria or viruses.
- cellular substrates such as endothelial cells
- This glycoprotein family is composed of heterodimers having one alpha chain (also referred to as "CD11") and one beta chain (also referred to as "CD18")
- CD11 alpha chain
- CD18 beta chain
- Mac-1 is a heterodimer found primarily on macrophages, granulocytes and large granular lymphocytes.
- LFA-1 is a heterodimer found on most lymphocytes (Springer, T.A. et aJL. Immunol. Rev. :1H-135 (1982)).
- pl50,95 has a tissue distribution similar to Mac-1, and also plays a role in cellular adhesion (Keizer, G. e£. a ⁇ . , Eur. J. Immunol. 15:1142-1147 (1985)).
- ICAM-1 interleukin-1
- One method to inhibit or prevent ICAM-1 from binding to its CD18 receptors is to utilize a molecule which competes with the CD18 receptors for binding to ICAM-1.
- One such competing molecule is an anti-ICAM-1 antibody.
- Mouse monoclonal antibodies to ICAM-1 have been shown to inhibit lymphocyte proliferative response requiring cell/cell interactions as well as inhibiting granulocyte attachment and subsequent migration through endothelial cell monolayers in vitro.
- Mouse anti-ICAM-1 antibodies are also known to inhibit leukocyte migration to inflamed lungs in rabbits, kidney allograft rejection and antigen-induced airway hyperreactivity in primates. See, e.g., Dustin et al, J. Immunol. 137:245 (1986) and egner et al Science 247:456 (1990).
- mouse monoclonal anti-ICAM-1 antibodies has therapeutic potential because the mouse anti-ICAM-1 can attenuate an inflammatory response by binding to ICAM-1 and interfering with leukocyte adhesion.
- treatment must be of short duration due to the innate immunogenicity of mouse immunoglobulin in primates.
- Anti-idiotypic antibodies are antibodies raised against another (primary) antibody, which recognize unique epitopes on the primary antibody. Some anti-idiotypes actually mimic the epitope that the primary antibody is directed against.
- certain anti-insulin anti-idiotypes act as agonists of the insulin receptor [Shechter et al, Anti-Idiotvpes, Receptors and Molecular Mimicry, p. 73 (D.S. Linthicum and N.R.
- Certain anti-morphine anti-idiotypes will bind to opiate receptors (Ng et al, Eur. _, . Pharmacol. 102:187, 1984). Certain anti-viral anti-idiotypes have elicited an immune response to the virus where the host has been immunized with the anti-idiotype. (See, e.g., Gaulton et al. J. Immunol. 137:2930, 1986). U.S. Patent No. 4,918,164 describes anti-tumor anti-idiotypes and their use in immunotherapy and immunoprophylaxis. Monoclonal anti-CD18 anti-idiotypic antibodies have been described in Hildreth et al., Mol. Immunol. 26:1155 (1989).
- This invention relates to a method for treating ICAM-1 dependent inflammation in a patient, which comprises adminstering to the patient a therapeutically effective dosage of an anti-ICAM-1 anti-idiotype (Ab2 ⁇ ) or a fragment thereof, wherein the Ab2 ⁇ or the fragment thereof, specifically recognizes an anti-ICAM-1 antibody (Abl) idiotype that inhibits the binding of ICAM-1 to the ICAM-1 receptor participating in the inflammation.
- the Ab2 ⁇ has conformational homology with the antigenic epitope of ICAM-1. Because of this conformational homology (or internal image) , administration of the Ab2 ⁇ to the patient results in the elicitation of anti-Ab2 ⁇ antibodies (Ab3) in the patient. At least one Ab3 (Ab3') mimics the Abl.
- the Ab3' will bind to the ICAM-1 and inhibit ICAM-1 function in adhesion, i.e., the Ab3' will inhibit ICAM-1 binding to the leukocyte receptor participating in the inflammation. As a result, the inflammation is reduced or eliminated.
- the Abl und Ab2 ⁇ antibodies can be prepared using procedures known in the art for producing antibodies, e.g. by immunopurification of polyclonal serum, by hybridoma technology or by recombinant cell culture technology. See, e.g. Kohler et al, P.N.A.S. USA 77(4):2197 (1980) and U.S. Patent No. 4,816,567.
- mice are initially immunized with ICAM-1. The mice are later sacrificed and their spleens removed. Spleen cells are fused with myeloma cells to produce hybridomas. The hybridomas are cultivated and their supernatants screened for anti-ICAM-1 activity, e.g. by radioimmunoassay (RIA) , enzyme-linked immunoassary (ELISA), or, preferably, by an aggregation assay as described in Rothlein et al. Hybridomas secreting monoclonal antibody (mAb) with the desired anti-ICAM-1 activity are cloned and cultivated to produce the Abl.
- RIA radioimmunoassay
- ELISA enzyme-linked immunoassary
- Hybridomas secreting monoclonal antibody (mAb) with the desired anti-ICAM-1 activity are cloned and cultivated to produce the Abl.
- the Ab2 ⁇ is a monoclonal antibody.
- Monoclonal Ab2 ⁇ can be prepared in a manner similar to the preparation of monoclonal Abl. Mice are initially immunized with Abl. The mice are later sacrificed and their spleens removed. Spleen cells are fused with myeloma cells to produce hybridomas. The hybridomas are cultivated and their supernatants screened for anti-Abl activity, e.g., by ELISA or RIA. Hybridomas secreting Mab with the desired anti-Abl activity are cloned and cultivated to produce the Ab2 ⁇ .
- Ab2 ⁇ can be administered to the patient.
- administration of Ab2 ⁇ utilizes subcutaneous or intramuscular injection of the Ab2 ⁇ in the presence of various adjuvants.
- the amount of Ab2 ⁇ to be administered will vary depending on the route of administration, type of inflammation, patient response, etc. but in general 0.1 mg to 100 mg of Ab2 ⁇ , preferably about 1 mg of Ab2 ⁇ , can be administered to the patient.
- the Ab2 ⁇ can be formulated with a suitable adjuvant in order to enhance the immunological response, including e.g., mineral gels such as aluminium hydroxide; surface active substances such as lysolecithin; pluronic polyols; polyanions; peptides and oil emulsions.
- a suitable adjuvant including e.g., mineral gels such as aluminium hydroxide; surface active substances such as lysolecithin; pluronic polyols; polyanions; peptides and oil emulsions.
- Ab2B useful in this invention includes whole antibodies and fragments, or any chemical modifications thereof, which mimic the desired ICAM-1 binding site that binds to the idiotype of Abl.
- Ab2 ⁇ fragments can be generated using various techniques known in the art, e.g., by proteolytic cleavage of the Ab2 ⁇ , or by recombinant construction. As an illustration of the present invention, the following examples are set forth in detail below:
- R6.5 Monoclonal anti-ICAM-1 antibody R6.5 (hereinafter referred to as "R6.5”), produced by hybridoma cell line R6'506*E9'B2 (ATCC HB 9580), at a concentration of 1 mg/ml, was incubated with keyhole limpet hemocyanin (KLH) (Sigma Chemical, St. Louis, MO.) also at 1 mg/ml, with 0.05 % glutaraldehyde (Sigma) for two hours at room temperature and dialysed against phosphate buffered saline (PBS), to produce a KLH-R6.5 conjugate.
- KLH keyhole limpet hemocyanin
- PBS phosphate buffered saline
- mice Six to eight week old femable Balb/c mice (Charles River Laboratories, Cambridge, MA.) were injected, intraperitoneally (i.p.), with 100 ⁇ g of the KLH-R6.5 conjugate in Complete Freunds Adjuvant (CFA) (Difco Labs) in a total of 0.4 ml per mouse. After three weeks mice were boosted with 100 ⁇ g of KLH-R6.5 conjugate with Incomplete Freunds Adjuvant (IFA) (Difco Labs) . The last boost (3 weeks later) was an i.p. injection of 5x10 R6.5 hybridoma cells (ATCC HB 9580) per mouse. Cells were irradiated, (1000R) before injection.
- CFA Complete Freunds Adjuvant
- IFA Incomplete Freunds Adjuvant
- mice were sacrificed and spleens removed for fusion.
- Spleen cells were fused with P3x63Ag8.653 myeloma cells at a ratio of 4:1 with PEG 4000 (VWR, Philadelphia, PA) .
- the fusion mixture was aliquoted into 96-well microtiter plates (Costar, Cambridge, MA).
- the resulting hybridoma supernatants were screened for anti-R6.5 activity by ELISA. Briefly, E.I.A.
- the plates were than washed 4x with DPBS and the substrate, 2,2-Azino-di(3-ethylbenzthiozoline Sulfonic Acid) (ABTS) dissolved in 0.1 M citrate buffer, pH 4.2 and 0.03 % hydrogen peroxide (ZYMED, San Franzisco, CA) was added.
- ABTS 2,2-Azino-di(3-ethylbenzthiozoline Sulfonic Acid)
- ZYMED San Franzisco, CA
- Optical density was read at 410 nM (Dynatech plate reader MR600) .
- One hybridoma of interest was cloned and subcloned by limiting dilution.
- the clone,, CA3/H10 secreted an IgG, class mAb (hereinafter referred to as "CA3”), as determined by Ouchterlony and ELISA.
- CA3 2,2-Azino-di(3-ethylbenzthi
- Pristine-primed Balb/c mice were injected i.p. with 5x 10 6 CA3/H10 cells in 0.5 ml of DPBS. Ascited tumor development was pronounced by day 14 after injection and mice were sacrificed by cervical dislocation. CA3-rich ascites fluid was collected and centrifuged to remove cells.
- An E.I.A. microtiter plate was coated with R6.5 or normal mouse IgG F(ab') 2 , 1 ⁇ g/well, overnight at 4°C in DPBS.
- the plates were washed 3x and blocked at 37°C for 1 hour with a 2 % bovine serum albumin (BSA) solution.
- BSA bovine serum albumin
- the BSA was then flicked out and replaced with 50 ⁇ l of soluble ICAM-1 (sICAM-1) (prepared as described in Marlin, S., et al. Nature 344, 70-72 (1990)) or control solution (25 ⁇ g/ml final concentration) and incubated for 30 minutes at 37°C.
- sICAM-1 soluble ICAM-1
- E.I.A. plates were coated with 1 ⁇ g/well of native or reduced sICAM-1 overnight at 4°C.
- Reduced sICAM-1 was prepared by incubating native sICAM-1 prepared as described in Marlin, et al (supra), in 1M 2-merca ⁇ toethanol (final concentration) at room temperatur for 30 minutes.
- a 2 % ovalbumin-coated plate (OA) was prepared as a negative control.
- the plates were washed 3x with DPBS and blocked with 2 % OA for 1 hour at 37°C. Blocking solution was replaced with 50 ⁇ l/well of either 2 % OA, R3.1 (100 ⁇ g/ml, control IgGl) mAb (prepared as described in Smith et al, J.
- Soluble ICAM-1 was run on an 8 % Laemmli SDS-polyacrylamide gel in a pH 6.9 sample buffer containing 6 % SDS, 4mM urea, 125 mM Tris, 4 mM EDTA, 0.25 % bromphenyl blue and 10 % glycerol.
- sICAM-1 was loaded at a concentration of 5 ⁇ g per lane in a final volume of 150 ⁇ l and run for 16 hrs at 45 volts. Transfer to nitrocellulose membranes was performed at 4°C for 2 hrs.
- Membranes were then washed 3x in TBST and incubated for 1 hour at room temperature with the appropriate anti-IgG alkaline phosphatase conjugated secondary antibody (Promega, Madison, WI.) .
- Nitrocellulose membranes were again washed 3x in TBST and visualized with a solution containing 0.33 mg/ml nitroblue tetrazolium (NBT) , 0.16 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) , 100 mM Tris-HCL pH 9.5, 100 mM NaCl and 5 mM MgCl 2 .
- NBT nitroblue tetrazolium
- BCIP 5-bromo-4-chloro-3-indolyl phosphate
- R6.5 was used at a concentration of 20 ⁇ l/ml as a positive control because it did not bind to reduced sICAM-1.
- the membrane was washed with 400 ⁇ l of TBST and the appropriately diluted secondary anti-IgG alkaline phosphatase-conjugated antibody was added.
- the membrane was then washed 3x with TBS to remove excess Tween-20 and color development was achieved by the addition of substrate containing NBT and BCIP. Color development was stopped by adding deionized water.
- H RESULTS
- the anti-ICAM-1 mAbs, R6.5 and RR1 have been shown to exhibit functional anti-adhesion properties.
- the aggregation of cells from the human lymphoid cell line, JY is dependent upon the interaction of ICAM-1 and LFA-1 leukocyte adhesion molecules and antibodies to both LFA-1 and ICAM-1 inhibit aggregation (Rothlein et al.).
- R6.5 and RR1 inhibited JY cell aggregation by 60 %;
- CA3 blocked the ability of R6.5 but not of RR1 to inhibit JY cell aggregation.
- CA3 as an immunogen.
- the characterization of CA3 suggested that it shared conformation homology with the epitope bound by R6.5.
- Rabbits were immunized with CA3 to induce a heterologous anti-antiidiotype (Ab3) response.
- An IgG preparation of rabbit anti-CA3 sera was tested for binding to sICAM-1.
- Figure 4 in an ELISA assay with solid phase sICAM-1, significant binding to ICAM-1 was detected at 200 ⁇ g/ml.
- Comparison of binding to native and to reduced sICAM-1 in an immunoblot showed significant binding to reduced sICAM-1 at 10-fold lower IgG concentrations than was detected with native sICAM-1 (Fig. 5).
- R6.5 bound to native sICAM-1 but no binding to reduced sICAM-1 was detected.
- Western blot analysis supported the binding of anti-CA3 to reduced ICAM-1 which migrates, as expected, at an apparent higher molecular weight (Fig. 6).
- Rabbit anti-CA3 was also tested for its ability to bind to cells expressing ICAM-1. As shown in Figure 7, rabbit anti-CA3 showed significant binding to JY cells which decreased with decreasing antibody concentration. That the binding of anti-CA3, like that of R6.5, was specific not only for ICAM-1 but also for the domains of the molecule that are functional in aggregation is indicated by the fact that the rabbit anti-CA3 inhibited JY cell aggregation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Procédé d'inhibition de réponse aux inflammatoires dépendant de ICAM-1 par immunisation d'un patient avec des anticorps anti-idiotypiques anti-ICAM-1 ou des fragments de ceux-ci. Les anticorps anti-idiotypiques anti-ICAM-1 sont également décrits et leur site de combinaison d'antigènes se lie à un idiotype d'un anticorps anti-ICAM-1 qui inhibe la liaison de ICAM-1 sur un récepteur de leukocytes de ICAM-1.A method of inhibiting response to ICAM-1-dependent inflammatory drugs by immunizing a patient with anti-idiotypic anti-ICAM-1 antibodies or fragments thereof. Anti-ICAM-1 anti-idiotypic antibodies are also described and their antigen-combining site binds to an idiotype of an anti-ICAM-1 antibody which inhibits binding of ICAM-1 to an ICAM leukocyte receptor -1.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59214790A | 1990-10-03 | 1990-10-03 | |
US592147 | 1996-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0551400A1 true EP0551400A1 (en) | 1993-07-21 |
EP0551400A4 EP0551400A4 (en) | 1993-10-13 |
Family
ID=24369494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19910918758 Withdrawn EP0551400A4 (en) | 1990-10-03 | 1991-10-02 | Method for treating inflammation using anti-idiotypic antibodies |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0551400A4 (en) |
JP (1) | JPH06504426A (en) |
AU (1) | AU8765391A (en) |
CA (1) | CA2092801A1 (en) |
WO (1) | WO1992006119A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107461A (en) * | 1990-07-20 | 2000-08-22 | Bayer Corporation | Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use |
US6130202A (en) * | 1990-07-20 | 2000-10-10 | Bayer Corporation | Antiviral methods |
US5629162A (en) * | 1991-06-11 | 1997-05-13 | The Center For Blood Research | Method of identifying agents which modulate ICAM-3 binding to LFA-1 |
US5525487A (en) * | 1992-01-27 | 1996-06-11 | Icos Corporation | DNA encoding I-CAM related protein |
US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
US6818743B1 (en) | 1992-01-27 | 2004-11-16 | Icos Corporation | I-CAM related protein |
US6100383A (en) * | 1992-01-27 | 2000-08-08 | Icos Corporation | Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions |
US5880268A (en) * | 1992-01-27 | 1999-03-09 | Icos Corporation | Modulators of the interaction between ICAM-R and αd /CD18 |
US5989843A (en) * | 1992-01-27 | 1999-11-23 | Icos Corporation | Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein |
US5532127A (en) * | 1992-01-27 | 1996-07-02 | Icos Corporation | Assay for 1-CAM related protein expression |
US6153395A (en) * | 1992-01-27 | 2000-11-28 | Icos Corporation | ICAM-related protein |
WO1993014776A1 (en) * | 1992-01-27 | 1993-08-05 | Icos Corporation | Icam-related protein |
FR2858326A1 (en) * | 2003-08-01 | 2005-02-04 | Abtech | Preparing antibodies that mimic a selected substance, useful particularly for activating or inhibiting biological processes, e.g. for inhibiting angiogenesis, comprises series of three immunizations |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
ATE79270T1 (en) * | 1989-03-09 | 1992-08-15 | Boehringer Ingelheim Pharma | USE OF INTERCELLULAR ADHAESION MOLECULES AND THEIR BINDING LIGANDS IN THE TREATMENT OF ASTHMA. |
-
1991
- 1991-10-02 AU AU87653/91A patent/AU8765391A/en not_active Abandoned
- 1991-10-02 WO PCT/US1991/007365 patent/WO1992006119A1/en not_active Application Discontinuation
- 1991-10-02 EP EP19910918758 patent/EP0551400A4/en not_active Withdrawn
- 1991-10-02 JP JP3517950A patent/JPH06504426A/en active Pending
- 1991-10-02 CA CA002092801A patent/CA2092801A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
IMMUNOLOGY vol. 67, no. 4, August 1989, OXFORD, GB pages 525 - 530 E. AUSTIN ET AL. 'Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36.' * |
MOLECULAR IMMUNOLOGY vol. 26, no. 12, 1989, OXFORD, GB pages 1155 - 1167 J. HILDRETH ET AL. 'Production and characterization of monoclonal anti-CD18 anti-idiotype antibodies.' * |
See also references of WO9206119A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU8765391A (en) | 1992-04-28 |
CA2092801A1 (en) | 1992-04-04 |
WO1992006119A1 (en) | 1992-04-16 |
EP0551400A4 (en) | 1993-10-13 |
JPH06504426A (en) | 1994-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Holmdahl et al. | Characterization of the antibody response in mice with type II collagen–induced arthritis, using monoclonal anti–type II collagen antibodies | |
KR900004420B1 (en) | Antibody for interleukin-1 | |
US6544749B1 (en) | Antibodies to leukemia inhibitory factor and their use in immunoassays | |
US5449760A (en) | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils | |
Volk et al. | Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule | |
Silverman et al. | Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. | |
EP0551400A1 (en) | Method for treating inflammation using anti-idiotypic antibodies | |
US6392020B1 (en) | Monoclonal antibody to the clonotypic structure of a T-cell receptor, a pharmaceutical compostion and a diagnostic reagent comprising the same | |
Guilbert et al. | Presence of natural autoantibodies in hyperimmunized mice. | |
Holmdahl et al. | Generation of monoclonal rheumatoid factors after immunization with collagen II‐anti‐collagen II immune complexes: an anti‐idiotypic antibody to anti‐collagen II is also a rheumatoid factor | |
US5625039A (en) | Anti-human IgE monoclonal antibodies | |
US5298420A (en) | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface | |
Silverman et al. | Structural characterization of the second major cross‐reactive idiotype group of human rheumatoid factors. Association with the VH4 Gene Family | |
Mackworth-Young et al. | Idiotypic markers of polyclonal B cell activation. Public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. | |
Whitaker et al. | Monoclonal idiotypic and anti-idiotypic antibodies produced by immunization with peptides specified by a region of human myelin basic protein mRNA and its complement | |
Bluestone et al. | Anti-idiotypes to monoclonal anti-H-2 antibodies. III. Syngeneic anti-idiotypes on antibodies induced by in vivo administration of xenogeneic anti-idiotypes. | |
Gill-Pazaris et al. | Properties of a minor cross-reactive idiotype associated with anti-p-azophenylarsonate antibodies of A/J mice. | |
Slaoui et al. | Idiotypic analysis of potential and available repertoires in the arsonate system. | |
Hirai et al. | Regulation of expression of a family of cross-reactive idiotypes. | |
Kaveri et al. | Monoclonal anti-idiotypic antibodies against human anti-thyroglobulin autoantibodies recognize idiotopes shared by disease-associated and natural anti-thyroglobulin autoantibodies | |
Barbouche et al. | Common idiotypes expressed on human, monoclonal, abnormal immunoglobulins and cryoglobulins with polyreaetive autoantibody activities | |
EP0428485A1 (en) | Novel antiidiotypic monoclonal antibodies | |
Lee et al. | Anti-IL-4 antibody inhibits antigen specific IgE response but fails to prevent chicken gamma globulin-induced active systemic anaphylaxis: evidence for the involvement of IgG antibodies | |
Singhai et al. | Evidence for the presence of idiotype-bearing regulatory T cells in which idiotype expression does not show linkage to either IgH alleles or the MHC. | |
Ley et al. | Isolation and characterization of the main allergen of Dermatophagoides farinae by monoclonal antibodies that recognize IgE related epitopes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930503 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
RHK1 | Main classification (correction) |
Ipc: C12P 21/08 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19930827 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19950503 |